Niki BioSolutions Partners with Global Alzheimer’s Platform Foundation to Deliver Plasma-Based APOE Genotyping for Bio-Hermes-002
Niki BioSolutions announced its subsidiary DiamiR will perform plasma-based APOE genotyping for the Global Alzheimer's Platform Foundation's Bio-Hermes-002 study cohort. The New York State-approved assay adds genetic risk data to banked samples without additional blood draws, and results will be integrated into the Bio-Hermes dataset.
Key figures
- Gap research sites
- 75
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.